Cardiovascular diseases remain the leading cause of death in the EU, claiming 1.7 million lives lost each year.

This first episode positions life course immunisation within the global health landscape, framing it alongside the UN Sustainable Development Goals, the WHO European Immunisation Agenda 2030 and broader health equity aims.

What are the causes for the steady and at times dramatic decline in vaccine confidence seen since the mid-90’s across certain age-groups and communities? Why has the public discourse changed?

Outbreaks of vaccine-preventable diseases are increasing at a time when funding for immunisation programmes is being cut.

Life sciences drive innovation in medicine, food and sustainable production, adding nearly €1.5 trillion in value to the EU economy and supporting 29 million jobs across the European Union.

Croatia, Estonia, France, Germany, Lithuania, Slovenia and Spain produced an information note highlighting the loss of confidence in science and health authorities, representing a major challenge for democracies.

New respiratory syncytial virus (RSV) vaccines have been approved in the USA for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 years and older.

Recommendations on the use of maternal respiratory syncytial virus (RSV) vaccines and long-acting RSV monoclonal antibodies (mAbs) to prevent severe RSV disease in infants were issued by the WHO Strategic Advisory Group of Experts (SAGE)